ライフサイエンスコーパス: SDMA

1 MA) and symmetrically dimethylated arginine (SDMA).

2 (ADMA), but not symmetric dimethylarginine (SDMA).

3 tivity] and with symmetric dimethylarginine (SDMA).

4 inine (ADMA) and symmetric dimethylarginine (SDMA).

5 es form symmetrically dimethylated arginine (SDMA).

6 thylarginine and symmetric dimethylarginine (SDMA).

7 of proteins with symmetric dimethylarginine (sDMA).

8 site enables PRMT1 to generate both ADMA and SDMA.

9 ividual variability in ADMA, l-arginine, and SDMA.

10 itive independent associations with ADMA and SDMA.

11 nical THW loop enables the enzyme to produce SDMA.

12 FSR inversely correlated with both ADMA and SDMA.

13 ake into the cell (ADMA and symmetrical DMA [SDMA]).

14 nt key serum metabolites, namely creatinine, SDMA, 2-hydroxyethanesulfonate, and aconitic acid.

15 sociation between increased plasma levels of SDMA, AGXT2 variants, and various cardiometabolic risk f

16 ctivity, and elevated plasma levels of ADMA, SDMA and BAIB, compared to wild-type littermates.

17 minant ADMA mark can block the occurrence of SDMA and MMA marks on the same substrate.

18 ADMA, SDMA and their combined sum, which we termed a dimethyla

19 Relationships between SDMA and traditional risk factors for graft function and

20 arginine (ADMA), symmetric dimethylarginine (SDMA), and N-monomethylarginine (MMA) were quantified at

21 AGXT2) regulates systemic levels of ADMA and SDMA, and also of beta-aminoisobutyric acid (BAIB)-a mod

22 ated with >/=1 of baseline citrulline, ADMA, SDMA, and MMA levels.

23 ginine (ADMA) and symmetric dimethyarginine (SDMA) are independent mortality predictors in atheroscle

24 ts stereo-isomer symmetric dimethylarginine (SDMA), are increased in alcoholic hepatitis patients, an

25 The potential role of SDMA as a risk marker in renal transplant recipients (RT

26 ts the levels of symmetric dimethylarginine (SDMA) at Arg-3 on histone H4, leading to the repression

27 dentify a novel regulatory renal pathway for SDMA by AGXT2.

28 essed serum levels of homoarginine, ADMA and SDMA by LC-MS/MS in 865 individuals from a prospective c

29 ine, ADMA, and symmetrical dimethylarginine (SDMA) by high-performance liquid chromatography in 49 hy

30 , including homocysteine, and serum ADMA and SDMA concentrations at population level.

31 1) were independently associated with higher SDMA concentrations.

32 thesis rate (ASR) and reduced NOx, ADMA, and SDMA concentrations.

33 inine (ADMA) and symmetric dimethylarginine (SDMA) concentrations in conditions reportedly associated

34 gest that PIWI family member SMEDWI-3 is one sDMA-containing chromatoid body protein for which methyl

35 atic reduction of the steady-state levels of sDMA-containing proteins in MTAP+ cells, even though no

36 and the arginine:ADMA ratio normalized, but SDMA did not.

37 s indicate that the higher energy barrier of SDMA formation (DeltaDeltaG(double dagger) = 3.2 kcal/mo

38 Due to the limited amount of SDMA formed, we carried out quantum mechanical calculati

39 f SDMA, suggesting that PRMT5 is the primary SDMA-forming enzyme in these cells.

40 tudy reveals unique energetic challenges for SDMA-forming methyltransferases and highlights the exqui

41 also support emerging studies indicative of sDMA function in stabilization of RNP granules and the P

42 d with ADMA) may explain the small amount of SDMA generated by M48F-PRMT1.

43 Elevated symmetric dimethylarginine (SDMA) has been shown to predict cardiovascular events an

44 emoglobin, ADMA, symmetric-dimethylarginine (SDMA), histidine-rich protein-2, and angiopoietin-2 were

45 ic and symmetric dimethylarginines (ADMA and SDMA) impair nitric oxide bioavailability and have been

46 Similarly, SDMA in the 4th quartile was independently associated wi

47 r data demonstrate a role for PRMT5-mediated SDMA in the context of RS-induced transcriptional induct

48 erves as the substrate for the C-glycosidase SdmA in the pathway.

49 We analyzed SDMA in the placebo arm of the Assessment of Lescol in R

50 nine and high circulating levels of ADMA and SDMA independently predict all-cause mortality in patien

51 s of homoarginine and high levels of ADMA or SDMA independently predicted all-cause mortality after a

52 zed as a cardiovascular risk marker, whereas SDMA is a novel marker for renal function and associated

53 e formation of symmetrical dimethylarginine (sDMA), is a nucleolin-associated protein whose localizat

54 exposure, C-reactive protein, serum ADMA and SDMA (LC-MS/MS), and thiols (homocysteine, cysteine, tau

55 In stable RTR, an elevated SDMA level is independently associated with increased ri

56 ated glomerular filtration rate, an elevated SDMA-level (4th quartile, >1.38 mumol/L) was associated

57 Amino acid analysis confirms that MMA and SDMA levels accumulate when ADMA levels are reduced.

58 atients were grouped into quartiles based on SDMA levels at study inclusion.

59 Another PRMT, PRMT7, also affects SDMA levels at the same site despite its unique monometh

60 ltered levels of PRMT5 activity (assessed by sDMA levels) in accord with changes in its localization.

61 there are major increases in global MMA and SDMA levels, as detected by type-specific antibodies.

62 mammalian enzymes capable of depositing the SDMA mark.

63 nsferase PRMT5 as the enzyme responsible for sDMA modification in these proteins.

64 Thus, sDMA modification is a signal that Aub is loaded with pi

65 vivo evidence demonstrating that Sm protein sDMA modification is required for snRNP biogenesis in hu

66 ation, whereas ubiquitous expression rescues sDMA modification of Sm proteins and male sterility.

67 thyltransferase 5 (PRMT5) is responsible for sDMA modification of Sm proteins.

68 ed grandchildless gene, is also required for sDMA modification of Sm proteins.

69 ase, PRMT7, are each required for Sm protein sDMA modification.

70 PRMT5-dependent symmetric dimethylarginine (SDMA) modification induced upon RS.

71 pe II methyltransferase capable of producing SDMA modifications in proteins.

72 irectly to the symmetrical dimethylarginine (sDMA)-modified arginine- and glycine-rich (RG-rich) doma

73 substrate for PRMT5 and that distribution of sDMA-modified nucleolin is altered by AS1411.

74 dart5 and valois causes the specific loss of sDMA-modified Sm proteins and studies in C. elegans show

75 We found that the unmodified, but not the sDMA-modified, RG domains of SmD1 and SmD3 associate wit

76 al modification, symmetric dimethylarginine (sDMA), of Aub is essential for piRNA biogenesis, transpo

77 he presence of symmetrical dimethylarginine (sDMA) on chromatoid body components and identify the ort

78 rst analysis, whether homoarginine, ADMA and SDMA predict venous thromboembolism (VTE) recurrence and

79 ic and symmetric dimethylarginines (ADMA and SDMA) predict and potentially contribute to end organ da

80 er asymmetric or symmetric dimethylarginine (SDMA), PRMT7 is unique in producing solely monomethylarg

81 inine (ADMA) and symmetric dimethlyarginine (SDMA) ratio (OR per 1 SD, 1.19; 95% CI: 1.02-1.41), N1-a

82 explain part of the pathogenic link between SDMA, renal function, and outcome.

83 human PRMT5, results in the complete loss of sDMA residues on spliceosomal Sm proteins.

84 pable of forming symmetric dimethylarginine (SDMA) residues as type II PRMTs.

85 oteins contain symmetrical dimethylarginine (sDMA) residues in vivo.

86 ified to contain symmetric dimethylarginine (sDMA) residues within their C-terminal tails.

87 els of symmetrically di-methylated arginine (SDMA) residues.

88 broblasts results in almost complete loss of SDMA, suggesting that PRMT5 is the primary SDMA-forming

89 the free energies of activation of ADMA and SDMA synthesis.

90 an PRMT9 shifts its product specificity from SDMA toward MMA.

91 SDMA was also formed when a GRG tripeptide was methylate

92 SDMA was high in children with SM.

93 In univariate analysis, SDMA was significantly associated with renal graft loss,

94 Plasma ADMA and SDMA were significantly higher in alcoholic hepatitis pa